This article was originally published in The Tan Sheet
Firm has not specifically discussed use of split labeling for its Inholtra Joint Pain line of analgesic/glucosamine combo products with FDA, as reported by "The Tan Sheet" (July 16, p. 4). Rather, Omni notes it was anonymously represented by law firm Sidley & Austin, which presented FDA reps with a mock-up version of a split label
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC